FDA Okay of Regeneron’s PD-1 Inhibitor Marks Entry of First Immunotherapy for Advanced Basal Cell Carcinoma
On February 9th, Regeneron and Sanofi announced that Libtayo (cemiplimab), a PD-1 Inhibitor, had received FDA approval for locally advanced basal cell carcinoma (BCC) and accelerated approval in metastatic BCC. …
Read More